Fig. 4
From: Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc
Bacterial-mediated RNAi of c-Myc extends survival of ApcΔISC mice. (A) Kaplan-Meier survival curves for 15-day ApcΔISC cohorts administered PBS (N = 14, red), 1 × 106 CFU SL7207/SCR (N = 12, blue), or 1 × 106 CFU SL7207/c-Myc (N = 12, green) (Mantel-Cox log rank test (PBS vs. c-Mycp = 0.003**, PBS vs. scrambled p = 0.197, scrambled vs. c-Mycp = 0.319). (B) Survival endpoint quantification of crypts from survival analysis staining positive for nuclear β-catenin. (C) Survival endpoint PCR analysis of small intestine from survival analysis mice demonstrating general absence of bacteria (survival days indicated). (D) PCR DNA analysis of ApcΔISC intestine 7 days following bacterial administration indicating variation in bacterial persistence. (E) c-Myc expression analysis of ApcΔISC intestine 7 days after bacterial administration. (F) Average number of nuclear β-catenin cells ApcΔISC crypts (N = 25) 7 days post bacteria administration (two-tailed Mann Whitney U- test, *p < 0.05, ***P < 0.001)